FDA Approves Trodelvy for Metastatic Triple-Negative Breast Cancer

THURSDAY, April 23, 2020 — Accelerated approval has been granted to Trodelvy (sacituzumab govitecan-hziy) to treat patients with metastatic triple-negative breast cancer who have received at least two previous therapies, the U.S. Food and Drug…
Source: Topamax